Despite the lack of effective treatments for most retinal dystrophies, recent advances in gene therapy, particularly the approval of Luxturna for RPE65-associated retinal dystrophies, offer new hope for therapeutic intervention, with several ongoing clinical trials targeting other subtypes [4]. Here, RPE65 is linked to Retinal dystrophy.